OrthoPediatrics (KIDS) Stock Price, News & Analysis

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KIDS shares.
View KIDS analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price targets for OrthoPediatrics' stock. Their KIDS share price targets range from $31.00 to $52.00. On average, they predict the company's stock price to reach $43.75 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for KIDS or view top-rated stocks among Wall Street analysts.

OrthoPediatrics' stock was trading at $32.51 on January 1st, 2024. Since then, KIDS shares have increased by 6.7% and is now trading at $34.70.
View the best growth stocks for 2024 here.

OrthoPediatrics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,040,000 shares, an increase of 10.5% from the March 15th total of 941,200 shares. Based on an average trading volume of 179,900 shares, the days-to-cover ratio is presently 5.8 days. Currently, 6.6% of the shares of the company are short sold.
View OrthoPediatrics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our KIDS earnings forecast.

OrthoPediatrics Corp. (NASDAQ:KIDS) released its earnings results on Wednesday, March, 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. The business earned $37.61 million during the quarter, compared to the consensus estimate of $37.59 million. OrthoPediatrics had a negative net margin of 14.10% and a negative trailing twelve-month return on equity of 5.03%.

OrthoPediatrics updated its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$203.0 million, compared to the consensus revenue estimate of $198.1 million.

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

OrthoPediatrics (KIDS) raised $52 million in an IPO on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

OrthoPediatrics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (2.11%), Riverbridge Partners LLC (2.07%), Conestoga Capital Advisors LLC (0.20%), Mutual of America Capital Management LLC (0.16%), Blue Trust Inc. (0.11%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include (Reynolds) Marie C Infante, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, Fred Hite, Gregory A Odle, Harold Ruf, Jennifer N Pritzker, Joseph W Hauser, Mark C Throdahl, Stephen F Burns and Terry D Schlotterback.
View institutional ownership trends.

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.